Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Core binding factor (CBF) acute myeloid leukemia (AML) is the most common cytogenetic subtype, characterized by specific chromosomal translocations like t(8;21) or inv(16).
• These aberrations result in fusion genes (AML1-ETO, CBFβ-MYH11) that impair the function of the core binding factor (CBF) transcription factor, crucial for normal hematopoiesis.
• Despite a generally favorable prognosis, current therapeutic strategies achieve cure rates of only around 50%, highlighting a significant unmet clinical need.

Purpose of the Study:

• To review current knowledge on the molecular mechanisms underlying CBF leukemia, including transcriptional dysregulation and aberrant signaling.
• To discuss cooperating genetic events that contribute to leukemogenesis in CBF-AML.
• To identify challenges and opportunities for translating research findings into improved clinical therapies for CBF-AML patients.

Main Methods:

• Literature review of studies on CBF-AML pathogenesis.
• Analysis of molecular alterations, including gene fusions and signaling pathway dysregulation.
• Synthesis of information on cooperating genetic events and their clinical implications.

Main Results:

• CBF-AML pathogenesis involves complex disruptions in transcriptional regulation and signaling pathways.
• Specific fusion genes (AML1-ETO, CBFβ-MYH11) are key drivers, but cooperating genetic events further promote leukemia development.
• Understanding these molecular underpinnings is essential for developing targeted therapeutic strategies.

Conclusions:

• Current therapies for CBF-AML are insufficient, necessitating novel treatment approaches.
• Further research into the molecular intricacies of CBF-AML, including signaling pathways and genetic cooperation, is critical.
• Translating these scientific insights into effective clinical practice remains a key challenge for improving patient outcomes.